Antibiotics
| PHA retargeted compounds |
| Azithromycin |
32744716 2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
Anti microbials
32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?
Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?
32546446 2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
32454071 2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.
32593831 2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.
Doxycycline and other Tetracyclins
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19
32314492 ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak
32267566 2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
32533795 2020. Further aspects of doxycycline therapy in COVID-19.
32379302 2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.
32552044 2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.
32574320 2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.
32566483 2020. Doxycycline as a potential partner of COVID-19 therapies.
Cefuroxime
32538276 2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.
'Aminoglycosides
32554149 2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.
Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen
Paromomycin
32579907 2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.
